首页 > 市场调查报告书 > 製药

骨疾病

市场调查报告书

商品编码

1528970

骨质疏鬆症药物市场 - 按类型、药物类别、给药途径、配销通路和预测，2024 年 - 2032 年

Osteoporosis Drugs Market - By Type, Drug Class, Route of Administration, Distribution Channel & Forecast, 2024 - 2032

出版日期: 2024年05月08日 | 出版商:

Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于全球骨质疏鬆症盛行率不断上升，2024年至2032年骨质疏鬆症药物市场规模的复合年增长率将达到4.6%。根据美国国立卫生研究院的数据，到 2023 年，骨质疏鬆症将影响全球超过 2 亿人。随着老年人的增长，骨密度自然下降，使他们更容易发生骨折和骨骼相关疾病。久坐的生活方式、营养不良和吸烟等生活方式因素进一步加剧了骨质疏鬆症的风险。

包括双磷酸盐、荷尔蒙疗法和生物製剂在内的新药的开发也将为管理和预防骨质流失提供更有效的选择。这些药物不仅有助于减缓骨吸收，还可以促进骨形成，进而改善整体骨骼健康。加强对骨质疏鬆症的认识活动和诊断筛检，以加强早期检测和治疗启动也将推动产品需求。

整个产业分为类型、药品类别、给药途径、配销通路和地区。

根据类型，继发性骨质疏鬆症领域的骨质疏鬆症药物市场规模预计将增长到 2032 年，因为它与导致骨质流失的可识别原因和潜在条件有关。已知甲状腺功能亢进、类风湿性关节炎和长期使用皮质类固醇等疾病会增加继发性骨质疏鬆症的风险。这些潜在疾病的管理正在为骨质疏鬆症药物的持续治疗铺平道路，以减轻骨质流失并降低骨折风险。

在分销管道方面，零售药房领域的骨质疏鬆药物市场将在2024年至2032年间录得显着增长。同时提供广泛的药物选择并确保可用性在当地社区。随着全球骨质疏鬆症盛行率的增加，特别是在老龄化人口中，从零售药局获取药物的便利性将鼓励治疗依从性和患者依从性。

预计到 2032 年，亚太地区骨质疏鬆药物产业规模将以惊人的速度成长。随着这一人群年龄的增长，与年龄相关的骨骼疾病的发生率将会激增，进一步需要有效的治疗方案。旨在改善医疗基础设施和促进预防性护理的政府措施也促进了区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 骨质疏鬆症盛行率增加
  - 骨折发生率不断增加
  - 药物开发的技术进步
- 产业陷阱与挑战
  - 治疗费用高
  - 严重病例疗效有限
成长潜力分析
监管环境
管道分析
波特的分析
PESTEL分析
未来市场趋势

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

主要趋势
原发性骨质疏鬆症
- 停经后骨质疏鬆症
- 老年骨质疏鬆症
- 特发性骨质疏鬆症
继发性骨质疏鬆症

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
双磷酸盐
RANK配体抑制剂
副甲状腺素类似物
荷尔蒙替代疗法（HRT）
选择性雌激素受体调节剂 (SERM)
其他药物类别

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

主要趋势
口服
可注射
其他给药途径

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药房
网路药房

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Amgen Inc.
Apotex Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
GSK plc
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Radius Health, Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited
UCB S.A.

简介目录

Product Code: 9420

Osteoporosis drugs market size will depict a 4.6% CAGR from 2024 to 2032 driven by the increasing prevalence of osteoporosis globally. As per the National Institute of Health, osteoporosis affected over 200 million people globally in 2023. The aging population, particularly in developed countries, is contributing significantly to the rise in osteoporosis cases. With the growth of aging people, bone density naturally decreases, making them more susceptible to fractures and bone-related disorders. Lifestyle factors, such as sedentary lifestyles, poor nutrition, and smoking are further exacerbating the risk of osteoporosis.

The development of new drugs, including bisphosphonates, hormone therapies, and biologics, will also offer more effective options for managing and preventing bone loss. These medications not only help in slowing down bone resorption but also promote bone formation for improving overall bone health. Increasing awareness campaigns and diagnostic screenings for osteoporosis to enhance early detection and treatment initiation will also drive product demand.

The overall industry is divided into type, drug class, route of administration, distribution channel, and region.

Based on type, the osteoporosis drugs market size from the secondary osteoporosis segment is set to grow up to 2032 due to its association with identifiable causes and underlying conditions that contribute to bone loss. Conditions, such as hyperthyroidism, rheumatoid arthritis, and prolonged use of corticosteroids are known to increase the risk of secondary osteoporosis. The management of these underlying conditions is making way for consistent treatment with osteoporosis medications to mitigate bone loss and reduce the risk of fractures.

In terms of distribution channels, the osteoporosis drugs market from the retail pharmacy segment will record a notable growth rate between 2024 and 2032. Retail pharmacies play a crucial role in distributing osteoporosis medications directly to consumers while offering a wide range of drug options and ensuring availability in local communities. With the globally increasing osteoporosis prevalence, particularly among the aging population, the convenience of obtaining medications from retail pharmacies will encourage treatment adherence and patient compliance.

Asia Pacific osteoporosis drugs industry size is anticipated to grow at an impressive pace through 2032. Increasing life expectancy and aging populations across countries like Japan, China, and South Korea are contributing significantly to the rising prevalence of osteoporosis. As this population grows older, the incidence of age-related bone disorders will surge, further necessitating effective treatment options. Government initiatives aimed at improving healthcare infrastructure and promoting preventive care are also bolstering the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of osteoporosis
  - 3.2.1.2 Growing incidence of fractures
  - 3.2.1.3 Technological advancements in drug development
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Limited efficacy in severe cases
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Primary osteoporosis
- 5.2.1 Postmenopausal osteoporosis
- 5.2.2 Senile osteoporosis
- 5.2.3 Idiopathic osteoporosis
5.3 Secondary osteoporosis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Bisphosphonates
6.3 RANK ligand inhibitors
6.4 Parathyroid hormone analogs
6.5 Hormone replacement therapy (HRT)
6.6 Selective estrogen receptor modulators (SERMs)
6.7 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Other route of administrations

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa